{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Restasis&page=17", "query": { "intervention": "Restasis", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 564, "total_pages": 57, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Restasis&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Restasis&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T00:19:58.843Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00096460", "title": "Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide and Rituximab", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Chemotherapy or Radiation therapy", "type": "RADIATION" }, { "name": "Non-myeloablative Conditioning regimen", "type": "DRUG" }, { "name": "Allogeneic transplant", "type": "PROCEDURE" }, { "name": "Autologous transplant", "type": "PROCEDURE" }, { "name": "Rituximab maintenance therapy", "type": "DRUG" }, { "name": "GVHD Prophylaxis", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 30, "start_date": "2004-08", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2023-01-05", "last_synced_at": "2026-10-24T00:19:58.843Z", "location_count": 30, "location_summary": "Duarte, California • La Jolla, California • Stanford, California + 23 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096460" }, { "nct_id": "NCT00429416", "title": "Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "L-leucyl-L-leucine Methyl Ester (LLME)", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)", "type": "BIOLOGICAL" }, { "name": "Hematopoietic stem cell transplantation (HSCT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2004-03", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-10-24T00:19:58.843Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00429416" }, { "nct_id": "NCT03025698", "title": "A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aplastic Anemia" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" }, { "name": "hATG", "type": "DRUG" }, { "name": "CsA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 51, "start_date": "2017-09-30", "completion_date": "2025-01-27", "has_results": true, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-24T00:19:58.843Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03025698" }, { "nct_id": "NCT01072526", "title": "Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dry Eye Syndromes" ], "interventions": [ { "name": "Euphrasia-based homeopathic therapy", "type": "DRUG" }, { "name": "Cyclosporin solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Missouri-Columbia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 7, "start_date": "2007-12", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2017-01-12", "last_synced_at": "2026-10-24T00:19:58.843Z", "location_count": 1, "location_summary": "Columbia, Missouri", "locations": [ { "city": "Columbia", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01072526" }, { "nct_id": "NCT04149678", "title": "Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Ozanimod", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2019-10-04", "completion_date": "2019-12-26", "has_results": false, "last_update_posted_date": "2020-08-24", "last_synced_at": "2026-10-24T00:19:58.843Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04149678" }, { "nct_id": "NCT03128034", "title": "211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome With Excess Blasts", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Mixed Phenotype Acute Leukemia", "Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Pretargeted Radioimmunotherapy", "type": "RADIATION" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 75, "start_date": "2017-10-24", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-24T00:19:58.843Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03128034" }, { "nct_id": "NCT00156364", "title": "Studies of Organ Transplantation in Animals and Man", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes Mellitus" ], "interventions": [], "intervention_types": [], "sponsor": "Michael Mauer, MD", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 655, "start_date": "1981-01", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2014-12-11", "last_synced_at": "2026-10-24T00:19:58.843Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00156364" }, { "nct_id": "NCT00104858", "title": "Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Prolymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Stage III Chronic Lymphocytic Leukemia", "Stage III Small Lymphocytic Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Small Lymphocytic Lymphoma", "T-Cell Large Granular Lymphocyte Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2004-12", "completion_date": "2018-03-30", "has_results": true, "last_update_posted_date": "2019-07-11", "last_synced_at": "2026-10-24T00:19:58.843Z", "location_count": 3, "location_summary": "Rochester, Minnesota • Seattle, Washington", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104858" }, { "nct_id": "NCT04795752", "title": "Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dry Eye", "Meibomian Gland Dysfunction" ], "interventions": [ { "name": "TearCare System", "type": "DEVICE" }, { "name": "Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Sight Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 345, "start_date": "2021-04-28", "completion_date": "2024-09-23", "has_results": true, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-10-24T00:19:58.843Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • La Jolla, California • Laguna Hills, California + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04795752" }, { "nct_id": "NCT01062555", "title": "Calcineurin Inhibitor Sparing After Kidney Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CNI Side Effects" ], "interventions": [ { "name": "Cyclosporine & Cellcept", "type": "DRUG" }, { "name": "Prograf & Cellcept", "type": "DRUG" }, { "name": "Low Dose CNI (Cyclosporine or FK) and Cellcept", "type": "DRUG" }, { "name": "Rapamune and Cellcept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 527, "start_date": "2006-10-01", "completion_date": "2014-04-03", "has_results": true, "last_update_posted_date": "2020-12-14", "last_synced_at": "2026-10-24T00:19:58.843Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01062555" } ] }